Drug Channels

MAY 27, 2020

Before you venture outside for your lockdown barbeque, check out these noteworthy items off the Drug Channels grill: Payers predict how COVID-19 will affect formularies Our analysis of the 2020 retail-to-mail shift AmerisourceBergen profiles biosimilars Plus, CVS pharmacy offers a clever way to measure appropriate social distancing.

Biosimilars 52

Biosimilars Specialty Pharmacies Hospitals 52

Drug Channels

NOVEMBER 9, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. After the event, every registrant will receive a link to download the complete slide deck and have an opportunity to watch a replay of the live event. Read on for full details on pricing and registration. d/b/a Drug Channels Institute.

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 98

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Drug Pricing 75

Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Drug Pricing 74

Drug Pricing Biosimilars Hospitals 74

Drug Channels

NOVEMBER 22, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

JULY 30, 2024

GoodRx joins the Humira biosimilar price war with Boehringer Ingelheim Averon revealed to be a new buying group for biosimilars for CVS Health and Cardinal Health Why the IRA will be bad news for 340B hospitals Plus, the June 2024 update to my all-time favorite chart. Did the FTC’s compelling interim report prove its case?

Biosimilars 40

Biosimilars Hospitals 40

Drug Channels

OCTOBER 11, 2022

Drug Distribution Industry Expands as COVID-19 Disruption Fades and Biosimilars Boom (press release) We’re offering special discounted pricing if you order before October 21, 2022! contains new data on hospital acquisitions and consolidation activity. Copyright © 2006-2022 Pembroke Consulting, Inc. Section 6.1.6.

Biosimilars 74

Biosimilars Hospitals Pharmaceutical Manufacturing Documentation 74

Drug Channels

OCTOBER 5, 2021

Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: Biosimilars Are Delivering Higher Profits for Drug Distributors (press release) We’re offering special discounted pricing if you order before October 15, 2021! Section 4.4.

Biosimilars 75

Biosimilars Pharmaceutical Manufacturing Hospitals Documentation 75

Drug Channels

NOVEMBER 24, 2020

My recent tweets have highlighted: doctors against step therapy, distribution of COVID-19 therapies, biosimilar savings, copay accumulator data, prospects for smaller PBMs, the new transparency rule, specialty pharmacy profit metrics, the future of oncology practices, and an update on Diplomat founder Phil Hagerman. to 1:15 p.m.

Specialty Pharmacies 52

Specialty Pharmacies Biosimilars Hospitals 52

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 40

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

However, FDA states that this exemption does not apply to corporate or hospital laboratories that employ licensed practitioners, and the agency says FD&C Act otherwise contains no exception or limitation for devices manufactured by laboratories. This comparison is misplaced.

Hospitals 81

Hospitals Immunization Immunity 81

PharmaShots

FEBRUARY 27, 2023

Addepalli Veeranjaneyulu and Shubhadeep Debabrata Sinha introduced the session by describing the function of PV in the safety profiles of biosimilars. To provide the audience with an Indian viewpoint, the presenters pointed out the country's requirements for biosimilar PV. Januvia is the FIC DPP-4 inh.

Biosimilars 40

Biosimilars Diabetes Packaging Hospitals 40

Drug Channels

JUNE 27, 2021

on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. P.S. Please join the nearly 12,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.

Hospitals 52

Hospitals Biosimilars Vaccines 52

PharmaShots

APRIL 13, 2023

Abbott spun off its hospital product business into an independent company called Hospira on the other hand its breakthrough drug Humira achieved a global sale of more than $0.8B by the sales of Humira 2006 Johnson & Johnson recorded global sales of $53.3B in the year 2006, thereby depicting a growth rate of 5.6%.

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

Drug Channels

OCTOBER 10, 2023

Drug Distribution Industry Gaining from Anti-Obesity Drugs and Provider-Administered Biosimilars (press release) We’re offering special discounted pricing if you order before October 20, 2023! Copyright © 2006-2023 Pembroke Consulting, Inc. pharmaceutical distribution industry. and Section 6.4.3. A new Section 6.2.2.

Specialty Pharmacies 40

Specialty Pharmacies Biosimilars Pharmaceutical Manufacturing Documentation 40

Drug Channels

DECEMBER 1, 2020

Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. Speaking of next year, Drug Channels Institute will host an exclusive live webinar, Drug Channels Outlook 2021 , on December 18, 2020, from 12:00 p.m. to 1:15 p.m. Click here to learn more and sign up. d/b/a Drug Channels Institute.

Vaccines 40

Vaccines Biosimilars Hospitals 40

Drug Channels

NOVEMBER 4, 2024

Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. As we demonstrate, health plans pay hospitals far above acquisition costs for biosimilars.

Biosimilars 98

Biosimilars Hospitals 98